Protective Effect of Caffeine and Chlorogenic Acids of Coffee in Liver Disease.

caffeine chlorogenic acid liver disease protective effect

Journal

Foods (Basel, Switzerland)
ISSN: 2304-8158
Titre abrégé: Foods
Pays: Switzerland
ID NLM: 101670569

Informations de publication

Date de publication:
20 Jul 2024
Historique:
received: 22 05 2024
revised: 12 07 2024
accepted: 17 07 2024
medline: 27 7 2024
pubmed: 27 7 2024
entrez: 27 7 2024
Statut: epublish

Résumé

Coffee is one of the most widely consumed beverages in the world due to its unique aroma and psychostimulant effects, mainly due to the presence of caffeine. In recent years, experimental evidence has shown that the moderate consumption of coffee (3/4 cups per day) is safe and beneficial to human health, revealing protective effects against numerous chronic metabolic diseases such as diabetes, cardiovascular, neurodegenerative, and hepatic diseases. This review focuses on two of coffee's main bioactive compounds, i.e., caffeine and chlorogenic acids, and their effects on the progression of chronic liver diseases, demonstrating that regular coffee consumption correlates with a lower risk of the development and progression of non-alcoholic steatohepatitis, viral hepatitis, liver cirrhosis, and hepatocellular carcinoma. In particular, this review analyzes caffeine and chlorogenic acid from a pharmacological point of view and explores the molecular mechanism through which these compounds are responsible for the protective role of coffee. Both bioactive compounds, therefore, have antifibrotic effects on hepatic stellate cells and hepatocytes, induce a decrease in connective tissue growth factor, stimulate increased apoptosis with anti-cancer effects, and promote a major inhibition of focal adhesion kinase, actin, and protocollagen synthesis. In conclusion, coffee shows many beneficial effects, and experimental data in favor of coffee consumption in patients with liver diseases are encouraging, but further prospective studies are needed to demonstrate its preventive and therapeutic role in chronic liver diseases.

Identifiants

pubmed: 39063364
pii: foods13142280
doi: 10.3390/foods13142280
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Auteurs

Daniela Di Pietrantonio (D)

Department of Innovative Technologies in Medicine and Dentistry, "G. d'Annunzio" University, Via dei Vestini 31, 66100 Chieti, Italy.

Valeria Pace Palitti (V)

Internal Medicine and Hepatology Unit, Azienda Sanitaria Locale, Via R. Paolini 47, 65125 Pescara, Italy.

Angelo Cichelli (A)

Department of Innovative Technologies in Medicine and Dentistry, "G. d'Annunzio" University, Via dei Vestini 31, 66100 Chieti, Italy.

Stefania Tacconelli (S)

Department of Neuroscience, Imaging and Clinical Science, "G. d'Annunzio" University, Via dei Vestini 31, 66100 Chieti, Italy.

Classifications MeSH